First Group Of Heart Failure Patients Treated With "Off-The-Shelf" Adult Stem Cells Successfully Pass Key Safety Milestone

First Group Of Heart Failure Patients Treated With "Off-The-Shelf" Adult Stem Cells Successfully Pass Key Safety Milestone
Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced successful achievement of the key safety milestone in the first low-dose cohort of patients treated with Revascor(tm), the proprietary allogeneic, or "off-the-shelf", universal adult stem cell product for congestive heart failure. Safety data from all 20 congestive heart failure patients enrolled in the multi-centre Phase 2 clinical trial by Mesoblast's United States-based sister company Angioblast Systems Inc.

Recently Reported Childhood Deaths From Influenza Are A Stark Reminder To Vaccinate Now

In recent weeks, a number of childhood deaths across the country have been linked to influenza. These tragic reports underscore the importance of preventing this serious and sometimes deadly disease with an annual flu vaccine. Influenza vaccine is still available and with influenza activity at a relatively high level across the country, now is the time for anyone who hasn't yet gotten the vaccine to do so. More at...